News Center

位置：

Honors Announcement

Group News

Media Reports

A medical aesthetic device developed by Hanlin Biotechnology, a subsidiary of Shijiazhuang Sihua Pharmaceutical Group, has been approved.

Category:

Honors Announcement

发布时间：2025-04-15

【概要描述】 Recently, the Class II medical device—medical recombinant collagen wound liquid dressing—developed by Hebei Hanlin Biotechnology Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group, has been successfully approved, providing more options for wound repair and care.

A medical aesthetic device developed by Hanlin Biotechnology, a subsidiary of Shijiazhuang Sihua Pharmaceutical Group, has been approved.

Recently, the Class II medical device—medical recombinant collagen wound liquid dressing—developed by Hebei Hanlin Biotechnology Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group, has been successfully approved, providing more options for wound repair and care.

To date, Hanlin Biotechnology has received approval for a total of 16 medical devices (1 Class I and 15 Class II) and 6 in vitro diagnostic reagents (3 Class I and 3 Class II). Among these, there are 6 medical aesthetic device products: sodium hyaluronate wound dressings, sodium hyaluronate wound gel dressings, sodium hyaluronate liquid wound dressings, recombinant humanized collagen wound dressings, recombinant humanized collagen wound gel dressings, and recombinant collagen liquid wound dressings.

In recent years, Hanlin Biotechnology has been driven by innovation, continuously introducing cutting-edge solutions in the medical aesthetics sector. While focusing on developing a comprehensive portfolio of products—including dressings, gels, and solutions—the company has also actively launched a range of novel formulations such as lyophilized products, significantly enhancing the sophistication of its offerings, elevating service standards, and strengthening its brand presence in the market.

Keywords:

Shijiazhuang Sihua Pharmaceutical Group’s dapagliflozin/metformin extended-release tablets (I) and arginine ibuprofen granules (0.2 g/0.4 g) — three new products — were approved on the same day.

Shijiazhuang Sihua Pharmaceutical Group’s 1000 mL Sodium Bicarbonate Ringer’s Injection, a scaled-up formulation, has been approved following evaluation.